GLP-1 receptor agonists
1 article · search the full text for this term
-
Assessment of Finerenone Safety and Efficacy in Individuals with Type 2 Diabetes and Chronic Kidney Disease
Abstract: Background: In this work, we provide strong evidence for the safety and efficacy of finerenone in people with type 2 diabetes and chronic kidney disease. Our goal is to improve patients' quality of life and general well-being through our research. Aim: Finerenone exhibited a significant decrease in the likelihood of renal and cardiovascular (CV) events in individuals with both type 2 diabetes and chronic kidney disease. This exploratory subgroup analysis …
Published in International Journal of Antibiotics · Vol. 1, Issue 2, 2024 · pp. 06–09 Read article